董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Mark G. Gilreath Chief Executive Officer and Director 49 370.90万美元 未持股 2016-03-21
James R. Balkcom Director 71 14.51万美元 未持股 2016-03-21
J. Scott Carter Director 46 12.94万美元 未持股 2016-03-21
Uri Geiger Director 58 12.19万美元 未持股 2016-03-21
David L. Kaufman Director 60 12.76万美元 未持股 2016-03-21
Rurik G. Vandevenne Director 51 13.13万美元 未持股 2016-03-21
William R. Enquist Director 59 19.70万美元 未持股 2016-03-21
R. Scott Huennekens Chairman 51 47.21万美元 未持股 2016-03-21
D. Scott Davis Director 64 14.51万美元 未持股 2016-03-21
David H. Mowry Director 53 19.70万美元 未持股 2016-03-21

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Mark G. Gilreath Chief Executive Officer and Director 49 370.90万美元 未持股 2016-03-21
David N. Gill President and Chief Financial Officer 61 177.33万美元 未持股 2016-03-21

董事简历

中英对照 |  中文 |  英文
Mark G. Gilreath

Mark G. Gilreath,他于2007年10月创立EndoChoice公司。他曾一直担任其总裁兼首席执行官,以及董事会成员。创立EndoChoice公司之前,他曾任职Given Imaging公司的执行委员会(从1999年到2008年),担任美洲总裁兼首席营销官。任职Given Imaging公司8年间,公司推出the PillCam Video Capsule,并通过有机增长从收入初创公司转变为纳斯达克上市公司,获得每年1.2亿美元的收入。从1992年到1999年,他曾担任PENTAX Medical公司(上市公司,制造消化内镜的视频内窥镜)的商业领导职务。加入PENTAX公司之前,他曾任职美国海军,负责海军情报,包括沙漠风暴行动。他持有the Fuqua School of Business at Duke University的工商管理硕士学位,以及Winthrop University的企业财务学士学位。他目前任职于the Fuqua/Coach K Center on Leadership & Ethics(COLE)、the Metro Atlanta Chamber of Commerce、the Medical Device Manufacturers Association (MDMA)的董事会。


Mark G. Gilreathhas served as our Chief Executive Officer since January 2013 and as our President from January 2013 until March 3 2016. Mr. Gilreath founded our subsidiary, EndoChoice, Inc., in October 2007 and has served as its President and Chief Executive Officer since inception. Prior to founding EndoChoice, Inc., Mr. Gilreath served on the Executive Committee, as the President of the Americas and as the Chief Marketing Officer at Given Imaging from 1999 to 2008. During his tenure at Given Imaging, the company launched the PillCam® Video Capsule and was transformed from a pre-revenue startup to a Nasdaq-listed company delivering $120 million in annual revenue, all through organic growth. From 1992 to 1999 Mr. Gilreath served in commercial leadership roles for PENTAX Medical, a public company manufacturing video endoscopes for GI endoscopy. Mr. Gilreath served in the U.S. Navy in naval intelligence, from 1989 to 1992 including during Operation Desert Storm. He currently serves on the board of directors of the Metro Atlanta Chamber of Commerce and the Medical Device Manufacturers Association MDMA. Mr. Gilreath holds a MBA from the Fuqua School of Business at Duke University and a B.Sc. in business finance from Winthrop University.
Mark G. Gilreath,他于2007年10月创立EndoChoice公司。他曾一直担任其总裁兼首席执行官,以及董事会成员。创立EndoChoice公司之前,他曾任职Given Imaging公司的执行委员会(从1999年到2008年),担任美洲总裁兼首席营销官。任职Given Imaging公司8年间,公司推出the PillCam Video Capsule,并通过有机增长从收入初创公司转变为纳斯达克上市公司,获得每年1.2亿美元的收入。从1992年到1999年,他曾担任PENTAX Medical公司(上市公司,制造消化内镜的视频内窥镜)的商业领导职务。加入PENTAX公司之前,他曾任职美国海军,负责海军情报,包括沙漠风暴行动。他持有the Fuqua School of Business at Duke University的工商管理硕士学位,以及Winthrop University的企业财务学士学位。他目前任职于the Fuqua/Coach K Center on Leadership & Ethics(COLE)、the Metro Atlanta Chamber of Commerce、the Medical Device Manufacturers Association (MDMA)的董事会。
Mark G. Gilreathhas served as our Chief Executive Officer since January 2013 and as our President from January 2013 until March 3 2016. Mr. Gilreath founded our subsidiary, EndoChoice, Inc., in October 2007 and has served as its President and Chief Executive Officer since inception. Prior to founding EndoChoice, Inc., Mr. Gilreath served on the Executive Committee, as the President of the Americas and as the Chief Marketing Officer at Given Imaging from 1999 to 2008. During his tenure at Given Imaging, the company launched the PillCam® Video Capsule and was transformed from a pre-revenue startup to a Nasdaq-listed company delivering $120 million in annual revenue, all through organic growth. From 1992 to 1999 Mr. Gilreath served in commercial leadership roles for PENTAX Medical, a public company manufacturing video endoscopes for GI endoscopy. Mr. Gilreath served in the U.S. Navy in naval intelligence, from 1989 to 1992 including during Operation Desert Storm. He currently serves on the board of directors of the Metro Atlanta Chamber of Commerce and the Medical Device Manufacturers Association MDMA. Mr. Gilreath holds a MBA from the Fuqua School of Business at Duke University and a B.Sc. in business finance from Winthrop University.
James R. Balkcom

James R. Balkcom,2009年8月以来,一直担任本公司董事;2009年8月至2015年2月,担任本公司董事长。2001年至今,他担任美国陆军部长的民间援助。此前,1999-2000,担任分销公司Pameco的董事长、首席执行官;1976起,他担任索纳成像公司Techsonic Industries的董事长、首席执行官,直到1994年该公司被出售。成立、出售该公司之后,他曾在一些商业银行、分销及高科技公司担任董事、董事长。在越南期间,他曾获得Bronze Star with Oak Leaf Cluster。他曾就读于Georgia Institute of Technology、United States Military Academy at West Point,在Harvard Business School获得财务方向的工商管理硕士学位。


James R. Balkcom served as Chairman of our Board from January 2013 until February 2015. In addition to being a member of the CEO Council of Council Capital, Mr. Balkcom currently serves as Civilian Aid to the Secretary of The Army, a position he has held since 2001. Prior to that, he served as Chairman and Chief Executive Officer of Pameco Corporation, a distribution company, from 1999 to 2000. He served as Chairman and Chief Executive Officer of Techsonic Industries, a sonar imaging company, from 1976 until its sale in 1994. Mr. Balkcom is on the board of directors of State Bank Financial Corporation. He has also served on the board of directors and as Chairman at several commercial banks, distribution and high-tech companies. Mr. Balkcom received a B.Sc. in Engineering from the United States Military Academy at West Point and a MBA in Finance from Harvard Business School.
James R. Balkcom,2009年8月以来,一直担任本公司董事;2009年8月至2015年2月,担任本公司董事长。2001年至今,他担任美国陆军部长的民间援助。此前,1999-2000,担任分销公司Pameco的董事长、首席执行官;1976起,他担任索纳成像公司Techsonic Industries的董事长、首席执行官,直到1994年该公司被出售。成立、出售该公司之后,他曾在一些商业银行、分销及高科技公司担任董事、董事长。在越南期间,他曾获得Bronze Star with Oak Leaf Cluster。他曾就读于Georgia Institute of Technology、United States Military Academy at West Point,在Harvard Business School获得财务方向的工商管理硕士学位。
James R. Balkcom served as Chairman of our Board from January 2013 until February 2015. In addition to being a member of the CEO Council of Council Capital, Mr. Balkcom currently serves as Civilian Aid to the Secretary of The Army, a position he has held since 2001. Prior to that, he served as Chairman and Chief Executive Officer of Pameco Corporation, a distribution company, from 1999 to 2000. He served as Chairman and Chief Executive Officer of Techsonic Industries, a sonar imaging company, from 1976 until its sale in 1994. Mr. Balkcom is on the board of directors of State Bank Financial Corporation. He has also served on the board of directors and as Chairman at several commercial banks, distribution and high-tech companies. Mr. Balkcom received a B.Sc. in Engineering from the United States Military Academy at West Point and a MBA in Finance from Harvard Business School.
J. Scott Carter

J. Scott Carter,2013年1月以来,一直是本公司董事。他从2006年6月起,担任风投公司 Sequoia Capital Operations, LLC的管理合伙人。他目前专注于服务、软件、医疗保健行业的投资业务。他现为AirStrip Technologies、Allston Trading、Implantable Provider Group、SimpliSafe、Telcare的董事。他曾在Sequoia参与对多家公司的投资,包括:Acton Pharmaceuticals, Amertiox, eCardio Diagnostics, Merlin Securities。加入Sequoia Capital之前,他在Summit Partners工作,专注于金融服务与科技行业。此前,他在J.P. Morgan及其前身工作过,也曾服务于美国前参议员Phil Gramm,担任过多个职务。他在Texas A&M University获得政治学士学位,在Darden School of Business at the University of Virginia获得工商管理硕士学位。


J. Scott Carter was formerly a managing member of Sequoia Capital Operations, LLC, a venture capital firm, from June 2006 until November 2015 where he focused on services, software and healthcare investments. Prior to joining Sequoia Capital, Mr. Carter was with Summit Partners where he focused on investments in the financial services and technology sectors. Earlier, he was with J.P. Morgan and its predecessor entities and served in various staff positions with former U.S. Senator Phil Gramm. Mr. Carter received a B.A. in Political Science from Texas A&M University and a MBA from the Darden School of Business at the University of Virginia.
J. Scott Carter,2013年1月以来,一直是本公司董事。他从2006年6月起,担任风投公司 Sequoia Capital Operations, LLC的管理合伙人。他目前专注于服务、软件、医疗保健行业的投资业务。他现为AirStrip Technologies、Allston Trading、Implantable Provider Group、SimpliSafe、Telcare的董事。他曾在Sequoia参与对多家公司的投资,包括:Acton Pharmaceuticals, Amertiox, eCardio Diagnostics, Merlin Securities。加入Sequoia Capital之前,他在Summit Partners工作,专注于金融服务与科技行业。此前,他在J.P. Morgan及其前身工作过,也曾服务于美国前参议员Phil Gramm,担任过多个职务。他在Texas A&M University获得政治学士学位,在Darden School of Business at the University of Virginia获得工商管理硕士学位。
J. Scott Carter was formerly a managing member of Sequoia Capital Operations, LLC, a venture capital firm, from June 2006 until November 2015 where he focused on services, software and healthcare investments. Prior to joining Sequoia Capital, Mr. Carter was with Summit Partners where he focused on investments in the financial services and technology sectors. Earlier, he was with J.P. Morgan and its predecessor entities and served in various staff positions with former U.S. Senator Phil Gramm. Mr. Carter received a B.A. in Political Science from Texas A&M University and a MBA from the Darden School of Business at the University of Virginia.
Uri Geiger

Uri Geiger,2014年1月以来,一直担任本公司董事。他现为Accelmed的管理合伙人,这是他在2009年参与创办的私募股权投资公司,专注于医疗器械公司的投资。此前,2006年5月至2008年12月,他是医疗技术公司Exalenz Bioscience Ltd的首席执行官。此前,他曾参与创办光学组件开发商GalayOr Networks,并在2001-2003年间担任首席执行官。他从2000年起,成为Dragon Variation Fund的创始合伙人,这是以色列首批对冲基金之一。1999年回到以色列之前,他在华尔街获得了资本市场方面的丰富知识和经验。他曾是Tel Aviv University’s Recanati School of Business的兼职教授,讲授私募股权和风投课程,出版了《Startup Companies and Venture Capital》、《From Concept to Wall Street》两本书。他在New York’s Columbia University Center for Law & Economics获得全球股票市场专业的博士学位。他还曾是以色列空军的少校。


Uri Geiger,is Strata Skin Sciences, Inc. Chairman of the Board. Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. He currently serves as Strata's Chairman of the Board of Directors. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdl in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York's Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies. Dr. Geiger served as the Chairman of the Board of Directors of Cogentix Medical from November 2016 until its sale in April 2018 and he is currently on the board of a number of public and private medical device companies. Dr. Geiger has served on the board of directors of NeuroPace, Inc., a publicly traded medical device company focused on epilepsy, since January 2023 and Minerva Surgical, Inc., a publicly traded medical device company focused on uterine healthcare, since February 2023.
Uri Geiger,2014年1月以来,一直担任本公司董事。他现为Accelmed的管理合伙人,这是他在2009年参与创办的私募股权投资公司,专注于医疗器械公司的投资。此前,2006年5月至2008年12月,他是医疗技术公司Exalenz Bioscience Ltd的首席执行官。此前,他曾参与创办光学组件开发商GalayOr Networks,并在2001-2003年间担任首席执行官。他从2000年起,成为Dragon Variation Fund的创始合伙人,这是以色列首批对冲基金之一。1999年回到以色列之前,他在华尔街获得了资本市场方面的丰富知识和经验。他曾是Tel Aviv University’s Recanati School of Business的兼职教授,讲授私募股权和风投课程,出版了《Startup Companies and Venture Capital》、《From Concept to Wall Street》两本书。他在New York’s Columbia University Center for Law & Economics获得全球股票市场专业的博士学位。他还曾是以色列空军的少校。
Uri Geiger,is Strata Skin Sciences, Inc. Chairman of the Board. Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. He currently serves as Strata's Chairman of the Board of Directors. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdl in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York's Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies. Dr. Geiger served as the Chairman of the Board of Directors of Cogentix Medical from November 2016 until its sale in April 2018 and he is currently on the board of a number of public and private medical device companies. Dr. Geiger has served on the board of directors of NeuroPace, Inc., a publicly traded medical device company focused on epilepsy, since January 2023 and Minerva Surgical, Inc., a publicly traded medical device company focused on uterine healthcare, since February 2023.
David L. Kaufman

David L. Kaufman,2009年10月以来,一直担任本公司董事。他现为私募股权公司Envest Holdings LLC的创始人、高级董事总经理。此前,他曾是The Vacation Store的董事长、首席执行官,他于1994年参与创办该公司。1987-1994,他任职于Cunard Line Ltd,先后担任财务副总裁、商业部门高级副总裁。他在IBM开启职业生涯,工作了7年,担任过各种财务管理职位。他现为America Swimming Pools, Cannonball, CoEnvest, EdLogics, Envest II, Envest III, Envest Holdings, Heritage Bank, NuScriptRx, Soluble Systems ,Specialty Coatings的董事;还是Old Dominion University Educational Foundation的委员会成员、Virginia Wesleyan College的主席。他在Emory University获得工商管理学士学位,在University of Michigan获得工商管理硕士学位。


David L. Kaufman has served as a director of our subsidiary, EndoChoice, Inc., since October 2009. Mr. Kaufman is a founding Member and Senior Managing Director of Envest Holdings LLC, a private equity firm, and serves as a member of the Envest II and Envest III Investment Committees. He previously served as Chairman and Chief Executive Officer of The Vacation Store, which he co-founded in 1994. Mr. Kaufman was employed with Cunard Line Ltd. from 1987 to 1994 where he started as Staff Vice President, Finance, and rose to the position of Senior Vice President, Business Groups. He started his career with IBM, serving for 7 years in various financial management positions. Mr. Kaufman is a member of the board of directors of America's Swimming Pool Co., Cannonball, CoEnvest, EdLogics, Envest Holdings, and NuScriptRx. He also serves on the board of Old Dominion University Educational Foundation and is Vice Chairman of Virginia Wesleyan College. Mr. Kaufman earned a BBA from Emory University and a MBA from the University of Michigan.
David L. Kaufman,2009年10月以来,一直担任本公司董事。他现为私募股权公司Envest Holdings LLC的创始人、高级董事总经理。此前,他曾是The Vacation Store的董事长、首席执行官,他于1994年参与创办该公司。1987-1994,他任职于Cunard Line Ltd,先后担任财务副总裁、商业部门高级副总裁。他在IBM开启职业生涯,工作了7年,担任过各种财务管理职位。他现为America Swimming Pools, Cannonball, CoEnvest, EdLogics, Envest II, Envest III, Envest Holdings, Heritage Bank, NuScriptRx, Soluble Systems ,Specialty Coatings的董事;还是Old Dominion University Educational Foundation的委员会成员、Virginia Wesleyan College的主席。他在Emory University获得工商管理学士学位,在University of Michigan获得工商管理硕士学位。
David L. Kaufman has served as a director of our subsidiary, EndoChoice, Inc., since October 2009. Mr. Kaufman is a founding Member and Senior Managing Director of Envest Holdings LLC, a private equity firm, and serves as a member of the Envest II and Envest III Investment Committees. He previously served as Chairman and Chief Executive Officer of The Vacation Store, which he co-founded in 1994. Mr. Kaufman was employed with Cunard Line Ltd. from 1987 to 1994 where he started as Staff Vice President, Finance, and rose to the position of Senior Vice President, Business Groups. He started his career with IBM, serving for 7 years in various financial management positions. Mr. Kaufman is a member of the board of directors of America's Swimming Pool Co., Cannonball, CoEnvest, EdLogics, Envest Holdings, and NuScriptRx. He also serves on the board of Old Dominion University Educational Foundation and is Vice Chairman of Virginia Wesleyan College. Mr. Kaufman earned a BBA from Emory University and a MBA from the University of Michigan.
Rurik G. Vandevenne

Rurik G. Vandevenne,2008年5月起,担任本公司董事。他于2003年加入River Cities Capital Funds,现为其董事;目前,他专注于成长阶段医疗保健信息技术与医疗器械方面的投资机会。此前,2000-2002,他任职于电子商务咨询公司Scient的策略部门,获得了早期阶段风投背景企业的工作经验。此前,1996-2000,他是Accenture的初级合伙人。他现为ABT Molecular Imaging、Continuity Control的董事,曾担任Pioneer Surgical、Fullscope的董事。他还是Center for Entrepreneurial Development、Southeast Medical Device Association SEMDA的董事,经常在Duke University担任客座讲师。他在Vanderbilt University获得机械工程学士学位,在Fuqua School of Business at Duke University获得工商管理硕士学位。


Rurik G. Vandevenne has been a member of our board of directors since May 2008. Mr. Vandevenne is a Director at River Cities Capital Funds, which he joined in 2003. Mr. Vandevenne focuses on growth stage healthcare information technology and medical devices investment opportunities. Prior to that, Mr. Vandevenne gained experience working with early stage venture backed companies in the strategy group of Scient, an eBusiness consulting firm, from 2000 to 2002. Prior to that, he worked from 1996 until 2000 at Accenture, where he was an associate. He serves on the boards of ABT Molecular Imaging, Continuity Control and Univa and was previously on the boards of Pioneer Surgical and Fullscope. Mr. Vandevenne serves on the board of directors of the Center for Entrepreneurial Development, the Southeast Medical Device Association SEMDA and is a frequent guest lecturer at Duke University. Mr. Vandevenne graduated from Vanderbilt University where he received his B.E. in Mechanical Engineering and earned his MBA from the Fuqua School of Business at Duke University.
Rurik G. Vandevenne,2008年5月起,担任本公司董事。他于2003年加入River Cities Capital Funds,现为其董事;目前,他专注于成长阶段医疗保健信息技术与医疗器械方面的投资机会。此前,2000-2002,他任职于电子商务咨询公司Scient的策略部门,获得了早期阶段风投背景企业的工作经验。此前,1996-2000,他是Accenture的初级合伙人。他现为ABT Molecular Imaging、Continuity Control的董事,曾担任Pioneer Surgical、Fullscope的董事。他还是Center for Entrepreneurial Development、Southeast Medical Device Association SEMDA的董事,经常在Duke University担任客座讲师。他在Vanderbilt University获得机械工程学士学位,在Fuqua School of Business at Duke University获得工商管理硕士学位。
Rurik G. Vandevenne has been a member of our board of directors since May 2008. Mr. Vandevenne is a Director at River Cities Capital Funds, which he joined in 2003. Mr. Vandevenne focuses on growth stage healthcare information technology and medical devices investment opportunities. Prior to that, Mr. Vandevenne gained experience working with early stage venture backed companies in the strategy group of Scient, an eBusiness consulting firm, from 2000 to 2002. Prior to that, he worked from 1996 until 2000 at Accenture, where he was an associate. He serves on the boards of ABT Molecular Imaging, Continuity Control and Univa and was previously on the boards of Pioneer Surgical and Fullscope. Mr. Vandevenne serves on the board of directors of the Center for Entrepreneurial Development, the Southeast Medical Device Association SEMDA and is a frequent guest lecturer at Duke University. Mr. Vandevenne graduated from Vanderbilt University where he received his B.E. in Mechanical Engineering and earned his MBA from the Fuqua School of Business at Duke University.
William R. Enquist

William R. Enquist,此前曾担任Stryker Corporation(Stryker)的全球内窥镜检查总裁(从1998年到2013年),也曾于2014年担任Stryker公司的顾问。从1998年到2013年,他曾领导Stryker公司的全球内窥镜集团成为刚性内窥镜视频市场的市场份额第一公司,以及领导全球销售额超过12亿美元。他于1986年加入Stryker公司,担任销售和营销组织。他任职于Firefly Medical公司的董事会。他持有the University of San Diego的工商管理学士学位,并完成了Harvard University的管理开发计划。


William R. Enquist formerly served as the President of Global Endoscopy for Stryker Corporation Stryker from 1998 until 2013 and served as an advisor to Stryker through 2014. From 1998 to 2013 Mr. Enquist led Stryker’s Global Endoscopy group to the number one market share position in the rigid endoscopic video market with global sales exceeding $1.2 billion. Mr. Enquist joined Stryker’s sales and marketing organization in 1986. He serves on the board of directors for Firefly Medical, Inc. Mr. Enquist earned a BBA from the University of San Diego and completed Harvard University's Program for Management Development.
William R. Enquist,此前曾担任Stryker Corporation(Stryker)的全球内窥镜检查总裁(从1998年到2013年),也曾于2014年担任Stryker公司的顾问。从1998年到2013年,他曾领导Stryker公司的全球内窥镜集团成为刚性内窥镜视频市场的市场份额第一公司,以及领导全球销售额超过12亿美元。他于1986年加入Stryker公司,担任销售和营销组织。他任职于Firefly Medical公司的董事会。他持有the University of San Diego的工商管理学士学位,并完成了Harvard University的管理开发计划。
William R. Enquist formerly served as the President of Global Endoscopy for Stryker Corporation Stryker from 1998 until 2013 and served as an advisor to Stryker through 2014. From 1998 to 2013 Mr. Enquist led Stryker’s Global Endoscopy group to the number one market share position in the rigid endoscopic video market with global sales exceeding $1.2 billion. Mr. Enquist joined Stryker’s sales and marketing organization in 1986. He serves on the board of directors for Firefly Medical, Inc. Mr. Enquist earned a BBA from the University of San Diego and completed Harvard University's Program for Management Development.
R. Scott Huennekens

R. Scott Huennekens,2002年4月起,担任本公司的总裁、首席执行官、董事。2000年1月至2002年3月,他是医学影像公司Digirad Corporation的总裁、首席执行官。他目前是 Medical Device Manufacturers Association MDMA的董事,这是一个全国性的行业协会。


R. Scott Huennekens,most recently served as the interim President and CEO of Hyperfine, Inc., a medical technology company focused on creating access to life-saving diagnostics and actionable data at the point of care, from June 2022 to October 2022.From August 2015 to December 2018, Mr. Huennekens served as the President, Chief Executive Officer and Chairman of the Board of Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop an advanced digital surgery platform. Prior to joining Verb Surgical, Mr. Huennekens was the President, Chief Executive Officer and a member of the Board of Directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider, and previously served as its Chief Financial Officer.
R. Scott Huennekens,2002年4月起,担任本公司的总裁、首席执行官、董事。2000年1月至2002年3月,他是医学影像公司Digirad Corporation的总裁、首席执行官。他目前是 Medical Device Manufacturers Association MDMA的董事,这是一个全国性的行业协会。
R. Scott Huennekens,most recently served as the interim President and CEO of Hyperfine, Inc., a medical technology company focused on creating access to life-saving diagnostics and actionable data at the point of care, from June 2022 to October 2022.From August 2015 to December 2018, Mr. Huennekens served as the President, Chief Executive Officer and Chairman of the Board of Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop an advanced digital surgery platform. Prior to joining Verb Surgical, Mr. Huennekens was the President, Chief Executive Officer and a member of the Board of Directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider, and previously served as its Chief Financial Officer.
D. Scott Davis

D. Scott Davis自2008年以来曾担任UPS董事长兼首席执行官。他于2006年被任命为副主席,并自2001年至2008年担任财务总监及司库,从1998年末至2000年初,他担任海外公司的首席执行官合伙人--一家百慕达再保险公司。他在2000年重新加入UPS作为金融副总裁。从1991年到1998年他担任多个领导职位,主要是在财务和会计领域。他在1986年加入了UPS时,该公司收购了俄勒冈州的二莫罗科技公司,在那里他曾担任财务总监,然后担任行政总裁。他还担任霍尼韦尔国际公司和EndoChoice公司的董事。


D. Scott Davis,Joined United Parcel Service, Inc. (UPS), a leading global provider of package delivery, specialized transportation, and logistics services, in 1986;Served as the non-Executive Chairman of UPS from September 2014 until May 2016 and as Chairman and Chief Executive Officer from January 2008 to September 2014;Served as Vice Chairman starting December 2006 and as Senior Vice President, Chief Financial Officer, and Treasurer starting January 2001 prior to serving as Chairman and Chief Executive Officer;Previously held various leadership positions at UPS, primarily in finance and accounting;Served a critical role in helping UPS to reinvent itself into a technology company;Chief Executive Officer of II Morrow Inc., a technology company and developer of general aviation and marine navigation instruments, prior to joining UPS;A Certified Public Accountant;Served on the Board of Directors of the Federal Reserve Bank of Atlanta from 2003 through 2009, and served as Chairman in 2009.
D. Scott Davis自2008年以来曾担任UPS董事长兼首席执行官。他于2006年被任命为副主席,并自2001年至2008年担任财务总监及司库,从1998年末至2000年初,他担任海外公司的首席执行官合伙人--一家百慕达再保险公司。他在2000年重新加入UPS作为金融副总裁。从1991年到1998年他担任多个领导职位,主要是在财务和会计领域。他在1986年加入了UPS时,该公司收购了俄勒冈州的二莫罗科技公司,在那里他曾担任财务总监,然后担任行政总裁。他还担任霍尼韦尔国际公司和EndoChoice公司的董事。
D. Scott Davis,Joined United Parcel Service, Inc. (UPS), a leading global provider of package delivery, specialized transportation, and logistics services, in 1986;Served as the non-Executive Chairman of UPS from September 2014 until May 2016 and as Chairman and Chief Executive Officer from January 2008 to September 2014;Served as Vice Chairman starting December 2006 and as Senior Vice President, Chief Financial Officer, and Treasurer starting January 2001 prior to serving as Chairman and Chief Executive Officer;Previously held various leadership positions at UPS, primarily in finance and accounting;Served a critical role in helping UPS to reinvent itself into a technology company;Chief Executive Officer of II Morrow Inc., a technology company and developer of general aviation and marine navigation instruments, prior to joining UPS;A Certified Public Accountant;Served on the Board of Directors of the Federal Reserve Bank of Atlanta from 2003 through 2009, and served as Chairman in 2009.
David H. Mowry

David H. Mowry,2013年2月至今,担任本公司的总裁、首席执行官;2013年6月至今,担任执行董事。他于2011年7月加入本公司,担任首席运营官;2012年11月,他被任命为临时总裁、首席执行官;2013年2月,正式担任总裁、首席执行官。他有着超过24年的医疗器械行业的经验。加入本公司之前,2010年7月至2011年7月,他担任Covidien plc的全球神经血管部门总裁,这是一个国际性的医疗产品供应商。2010年1月至2010年7月,他担任ev3 Inc的高级副总裁、全球心血管总裁,这是一个全球性的血管内置产品供应商,在2010年7月被Covidien收购。2007年8月至2010年1月,他是ev3的全球运营高级副总裁。此前,2006年11月至2007年10月,他担任ev3心血管理运营副总裁。加入ev3之前,2002年2月至2006年11月,他在 Zimmer Holdings的Zimmer Spine分部担任运营与物流副总裁,这是一个重建与脊柱植入物、外伤及相关整形外科产品的公司。加入Zimmer之前,他是医疗器械公司HeartStent Corp的总裁、首席运营官。他毕业于纽约的United States Military Academy in West Point,获得工程与数学学位。


David H. Mowry was appointed as the Company's Chief Executive Officer and a member of the Board on July 8 2019. Prior to joining Cutera, from May 2016 to October 2018 Mr. Mowry served as President and Chief Executive Officer, as well as a member of the Board of Directors, of Vyaire Medical, a global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to his assignment at Vyaire, Mr. Mowry served as Executive Vice President and Chief Operating Officer and member of the Board of Directors of Wright Medical Group N.V., a global medical device company focused on extremities and biologics products, from October 2015 to May 2016 and during this time period he was also a member of the Board of Directors of EndoChoice Holdings, Inc., a company focused on the manufacturing and commercialization of platform technologies relating to the treatment of gastrointestinal conditions. Prior to Mr. Mowry's assignment at Wright Medical Group, he served as President and Chief Executive Officer and member of the Board of Directors of Tornier N.V. from February 2013 until October 2015 at which time Tornier and Wright Medical Group merged, and prior to that, as Chief Operating Officer of Tornier from 2011 to 2013. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine from February 2002 until October 2006. Mr. Mowry has held executive leadership positions over his thirty year medical device career at Covidien plc, ev3 Inc. and Zimmer Spine, Inc. Mr. Mowry is on the Board of directors of Alphatec Holdings, Inc., a public medical technology company that designs, develops, and markets products for the surgical treatment of spine disorders. Mr. Mowry received a B.S. degree in Engineering from the United States Military Academy at West Point.
David H. Mowry,2013年2月至今,担任本公司的总裁、首席执行官;2013年6月至今,担任执行董事。他于2011年7月加入本公司,担任首席运营官;2012年11月,他被任命为临时总裁、首席执行官;2013年2月,正式担任总裁、首席执行官。他有着超过24年的医疗器械行业的经验。加入本公司之前,2010年7月至2011年7月,他担任Covidien plc的全球神经血管部门总裁,这是一个国际性的医疗产品供应商。2010年1月至2010年7月,他担任ev3 Inc的高级副总裁、全球心血管总裁,这是一个全球性的血管内置产品供应商,在2010年7月被Covidien收购。2007年8月至2010年1月,他是ev3的全球运营高级副总裁。此前,2006年11月至2007年10月,他担任ev3心血管理运营副总裁。加入ev3之前,2002年2月至2006年11月,他在 Zimmer Holdings的Zimmer Spine分部担任运营与物流副总裁,这是一个重建与脊柱植入物、外伤及相关整形外科产品的公司。加入Zimmer之前,他是医疗器械公司HeartStent Corp的总裁、首席运营官。他毕业于纽约的United States Military Academy in West Point,获得工程与数学学位。
David H. Mowry was appointed as the Company's Chief Executive Officer and a member of the Board on July 8 2019. Prior to joining Cutera, from May 2016 to October 2018 Mr. Mowry served as President and Chief Executive Officer, as well as a member of the Board of Directors, of Vyaire Medical, a global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to his assignment at Vyaire, Mr. Mowry served as Executive Vice President and Chief Operating Officer and member of the Board of Directors of Wright Medical Group N.V., a global medical device company focused on extremities and biologics products, from October 2015 to May 2016 and during this time period he was also a member of the Board of Directors of EndoChoice Holdings, Inc., a company focused on the manufacturing and commercialization of platform technologies relating to the treatment of gastrointestinal conditions. Prior to Mr. Mowry's assignment at Wright Medical Group, he served as President and Chief Executive Officer and member of the Board of Directors of Tornier N.V. from February 2013 until October 2015 at which time Tornier and Wright Medical Group merged, and prior to that, as Chief Operating Officer of Tornier from 2011 to 2013. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine from February 2002 until October 2006. Mr. Mowry has held executive leadership positions over his thirty year medical device career at Covidien plc, ev3 Inc. and Zimmer Spine, Inc. Mr. Mowry is on the Board of directors of Alphatec Holdings, Inc., a public medical technology company that designs, develops, and markets products for the surgical treatment of spine disorders. Mr. Mowry received a B.S. degree in Engineering from the United States Military Academy at West Point.

高管简历

中英对照 |  中文 |  英文
Mark G. Gilreath

Mark G. Gilreath,他于2007年10月创立EndoChoice公司。他曾一直担任其总裁兼首席执行官,以及董事会成员。创立EndoChoice公司之前,他曾任职Given Imaging公司的执行委员会(从1999年到2008年),担任美洲总裁兼首席营销官。任职Given Imaging公司8年间,公司推出the PillCam Video Capsule,并通过有机增长从收入初创公司转变为纳斯达克上市公司,获得每年1.2亿美元的收入。从1992年到1999年,他曾担任PENTAX Medical公司(上市公司,制造消化内镜的视频内窥镜)的商业领导职务。加入PENTAX公司之前,他曾任职美国海军,负责海军情报,包括沙漠风暴行动。他持有the Fuqua School of Business at Duke University的工商管理硕士学位,以及Winthrop University的企业财务学士学位。他目前任职于the Fuqua/Coach K Center on Leadership & Ethics(COLE)、the Metro Atlanta Chamber of Commerce、the Medical Device Manufacturers Association (MDMA)的董事会。


Mark G. Gilreathhas served as our Chief Executive Officer since January 2013 and as our President from January 2013 until March 3 2016. Mr. Gilreath founded our subsidiary, EndoChoice, Inc., in October 2007 and has served as its President and Chief Executive Officer since inception. Prior to founding EndoChoice, Inc., Mr. Gilreath served on the Executive Committee, as the President of the Americas and as the Chief Marketing Officer at Given Imaging from 1999 to 2008. During his tenure at Given Imaging, the company launched the PillCam® Video Capsule and was transformed from a pre-revenue startup to a Nasdaq-listed company delivering $120 million in annual revenue, all through organic growth. From 1992 to 1999 Mr. Gilreath served in commercial leadership roles for PENTAX Medical, a public company manufacturing video endoscopes for GI endoscopy. Mr. Gilreath served in the U.S. Navy in naval intelligence, from 1989 to 1992 including during Operation Desert Storm. He currently serves on the board of directors of the Metro Atlanta Chamber of Commerce and the Medical Device Manufacturers Association MDMA. Mr. Gilreath holds a MBA from the Fuqua School of Business at Duke University and a B.Sc. in business finance from Winthrop University.
Mark G. Gilreath,他于2007年10月创立EndoChoice公司。他曾一直担任其总裁兼首席执行官,以及董事会成员。创立EndoChoice公司之前,他曾任职Given Imaging公司的执行委员会(从1999年到2008年),担任美洲总裁兼首席营销官。任职Given Imaging公司8年间,公司推出the PillCam Video Capsule,并通过有机增长从收入初创公司转变为纳斯达克上市公司,获得每年1.2亿美元的收入。从1992年到1999年,他曾担任PENTAX Medical公司(上市公司,制造消化内镜的视频内窥镜)的商业领导职务。加入PENTAX公司之前,他曾任职美国海军,负责海军情报,包括沙漠风暴行动。他持有the Fuqua School of Business at Duke University的工商管理硕士学位,以及Winthrop University的企业财务学士学位。他目前任职于the Fuqua/Coach K Center on Leadership & Ethics(COLE)、the Metro Atlanta Chamber of Commerce、the Medical Device Manufacturers Association (MDMA)的董事会。
Mark G. Gilreathhas served as our Chief Executive Officer since January 2013 and as our President from January 2013 until March 3 2016. Mr. Gilreath founded our subsidiary, EndoChoice, Inc., in October 2007 and has served as its President and Chief Executive Officer since inception. Prior to founding EndoChoice, Inc., Mr. Gilreath served on the Executive Committee, as the President of the Americas and as the Chief Marketing Officer at Given Imaging from 1999 to 2008. During his tenure at Given Imaging, the company launched the PillCam® Video Capsule and was transformed from a pre-revenue startup to a Nasdaq-listed company delivering $120 million in annual revenue, all through organic growth. From 1992 to 1999 Mr. Gilreath served in commercial leadership roles for PENTAX Medical, a public company manufacturing video endoscopes for GI endoscopy. Mr. Gilreath served in the U.S. Navy in naval intelligence, from 1989 to 1992 including during Operation Desert Storm. He currently serves on the board of directors of the Metro Atlanta Chamber of Commerce and the Medical Device Manufacturers Association MDMA. Mr. Gilreath holds a MBA from the Fuqua School of Business at Duke University and a B.Sc. in business finance from Winthrop University.
David N. Gill

David N. Gill,他于2014年8月加入EndoChoice公司,担任其首席财务官。他曾从事医疗设备和生命科学行业20多年。此前,他曾担任INC Research公司(一个临床研究组织)的首席财务官(从2011年到2013年),此前曾担任董事会成员兼审计委员会主席(从2007年到2010年)。他曾担任TransEnterix公司(一个私人外科产品公司)的首席财务官(从2009年到2011年)。此前,他曾担任NxStage Medical公司(一个上市的透析设备的公司)的首席财务官兼财务主管(从2005年到2006年)。从2006年到2009年,他曾担任两个公共生命科学公司(LeMaitre Vascular公司、Isotis Biologics公司),以及一些私人生命科学公司的董事兼审计委员会主席。职业生涯早期,他曾担任CTI Molecular Imaging公司(医学成像上市公司)的高级副总裁兼首席财务官(从2002年到2004年),也曾担任Interland公司(上市电信公司)的总裁、首席运营官和董事(从2000年到2001年)、Novoste Corporation(上市医疗器械公司)的首席运营官和首席财务官(从1996年到2000年)、Dornier Medical Systems公司(一个私人泌尿道设备公司)的执行领导职务(从1990年到1995年),并于1992年当选总裁。他持有Wake Forest University的会计学士学位(以优异成绩获得),以及Emory University的荣誉工商管理硕士学位。他此前是注册会计师。他目前任职于Cempra Pharmaceuticals公司和Histogenics Corporation的董事会,并担任审计委员会主席。


David N. Gill became a director of the Company effective May 29 2018 and chairs our Audit Committee. Mr. Gill served as the President and Chief Financial Officer of EndoChoice, Inc., a medical device company focused on gastrointestinal disease from April 2016 through the sale of the company in November 2016 and as Chief Financial Officer from August 2014 to April 2016. Previously, he served as the Chief Financial Officer of INC Research now known as Syneos, a clinical research organization, from February 2011 to August 2013 after having served as a board member and its Audit Committee chairman from 2007 to 2010. Mr. Gill currently serves on the boards of Melinta Therapeutics, Inc., an infectious disease company, Strongbridge Biopharma, a rare disease company, Evolus, Inc., an aesthetics company, and YmAbs Therapeutics, Inc. an immuno-oncology company. Mr. Gill previously served as a director of Histogenics until July 2019. Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several medical device companies including TransEnterix, NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical. Mr. Gill holds a B.S. degree, cum laude, in Accounting from Wake Forest University and an M.B.A. degree, with honors, from Emory University, and was formerly a certified public accountant.
David N. Gill,他于2014年8月加入EndoChoice公司,担任其首席财务官。他曾从事医疗设备和生命科学行业20多年。此前,他曾担任INC Research公司(一个临床研究组织)的首席财务官(从2011年到2013年),此前曾担任董事会成员兼审计委员会主席(从2007年到2010年)。他曾担任TransEnterix公司(一个私人外科产品公司)的首席财务官(从2009年到2011年)。此前,他曾担任NxStage Medical公司(一个上市的透析设备的公司)的首席财务官兼财务主管(从2005年到2006年)。从2006年到2009年,他曾担任两个公共生命科学公司(LeMaitre Vascular公司、Isotis Biologics公司),以及一些私人生命科学公司的董事兼审计委员会主席。职业生涯早期,他曾担任CTI Molecular Imaging公司(医学成像上市公司)的高级副总裁兼首席财务官(从2002年到2004年),也曾担任Interland公司(上市电信公司)的总裁、首席运营官和董事(从2000年到2001年)、Novoste Corporation(上市医疗器械公司)的首席运营官和首席财务官(从1996年到2000年)、Dornier Medical Systems公司(一个私人泌尿道设备公司)的执行领导职务(从1990年到1995年),并于1992年当选总裁。他持有Wake Forest University的会计学士学位(以优异成绩获得),以及Emory University的荣誉工商管理硕士学位。他此前是注册会计师。他目前任职于Cempra Pharmaceuticals公司和Histogenics Corporation的董事会,并担任审计委员会主席。
David N. Gill became a director of the Company effective May 29 2018 and chairs our Audit Committee. Mr. Gill served as the President and Chief Financial Officer of EndoChoice, Inc., a medical device company focused on gastrointestinal disease from April 2016 through the sale of the company in November 2016 and as Chief Financial Officer from August 2014 to April 2016. Previously, he served as the Chief Financial Officer of INC Research now known as Syneos, a clinical research organization, from February 2011 to August 2013 after having served as a board member and its Audit Committee chairman from 2007 to 2010. Mr. Gill currently serves on the boards of Melinta Therapeutics, Inc., an infectious disease company, Strongbridge Biopharma, a rare disease company, Evolus, Inc., an aesthetics company, and YmAbs Therapeutics, Inc. an immuno-oncology company. Mr. Gill previously served as a director of Histogenics until July 2019. Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several medical device companies including TransEnterix, NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical. Mr. Gill holds a B.S. degree, cum laude, in Accounting from Wake Forest University and an M.B.A. degree, with honors, from Emory University, and was formerly a certified public accountant.